The document discusses different approaches to test teardown, including in-line teardown where teardown logic is placed directly in the test method. It notes that in-line teardown can be implemented using try/finally blocks or guard clauses. The document also covers implicit teardown, delegated teardown, and variations like teardown guard clauses and naive in-line teardown.
This document discusses the need for medical device companies to conduct deep due diligence when assessing new products given the evolving U.S. healthcare system's new focus on comparative and economic effectiveness. It outlines key clinical and economic questions that must be answered through compelling data to demonstrate improved outcomes and reduced societal costs. It differentiates between "me too" products that need prove parity and "innovative" products that could see exceptional opportunity but require rigorous studies. It recommends connecting with clinical and administrative communities and developing cost models to realistically assess new products under emerging public policies. External support from consultants is also advised.
The document provides guidance for technology providers (sellers) and product manufacturers/marketers (buyers) on improving the success of technology deals. For sellers, it recommends focusing on why the technology matters, targeting appropriate buyers, educating oneself on relevant markets, filing patents, and understanding how the technology fits within existing IP. For buyers, it suggests being open to early-stage deals, researching applications/markets thoroughly, engaging technology experts, proposing reasonable terms, and accepting assistance offered. The overall guidance is to keep the other party's interests in mind throughout the process to achieve a better outcome for both sides.
This document provides an introduction and overview of Trilogy Associates, a consulting practice that facilitates business growth and commercialization of new medical products. The practice focuses on markets, technologies, and business development in medical and life science fields. It was founded in 1989 and has worked with over 50 clients on opportunities including strategy, market research, partnering, technology evaluation, and product development.
This document discusses voice-of-the-customer (VOC) programs. It argues that customers are a company's most valuable asset, so it is important to understand their perspectives through VOC programs. The document provides 10 hints for effective VOC programs, such as knowing your customers, having a clear objective, compensating respondents, and following up on findings. It encourages companies to engage Trilogy Associates as a partner to help design and implement successful VOC programs.
Addressing the New Realities of Tomorrow\'s Healthcare Environmenttrilogy
The document discusses the need for medical product suppliers to conduct deep due diligence when assessing new products to address the evolving U.S. healthcare system's focus on comparative effectiveness. This means new products must prove they are at least as clinically effective as existing options and more economically effective through reduced costs. Suppliers will need to answer questions about clinical outcomes, economic impacts, and influence on reimbursement policies with compelling data. While "me too" products can easily prove parity, "innovative" products promising better outcomes will require rigorous studies. The document outlines steps and resources needed to properly evaluate new products under these new healthcare realities.
The document discusses different approaches to test teardown, including in-line teardown where teardown logic is placed directly in the test method. It notes that in-line teardown can be implemented using try/finally blocks or guard clauses. The document also covers implicit teardown, delegated teardown, and variations like teardown guard clauses and naive in-line teardown.
This document discusses the need for medical device companies to conduct deep due diligence when assessing new products given the evolving U.S. healthcare system's new focus on comparative and economic effectiveness. It outlines key clinical and economic questions that must be answered through compelling data to demonstrate improved outcomes and reduced societal costs. It differentiates between "me too" products that need prove parity and "innovative" products that could see exceptional opportunity but require rigorous studies. It recommends connecting with clinical and administrative communities and developing cost models to realistically assess new products under emerging public policies. External support from consultants is also advised.
The document provides guidance for technology providers (sellers) and product manufacturers/marketers (buyers) on improving the success of technology deals. For sellers, it recommends focusing on why the technology matters, targeting appropriate buyers, educating oneself on relevant markets, filing patents, and understanding how the technology fits within existing IP. For buyers, it suggests being open to early-stage deals, researching applications/markets thoroughly, engaging technology experts, proposing reasonable terms, and accepting assistance offered. The overall guidance is to keep the other party's interests in mind throughout the process to achieve a better outcome for both sides.
This document provides an introduction and overview of Trilogy Associates, a consulting practice that facilitates business growth and commercialization of new medical products. The practice focuses on markets, technologies, and business development in medical and life science fields. It was founded in 1989 and has worked with over 50 clients on opportunities including strategy, market research, partnering, technology evaluation, and product development.
This document discusses voice-of-the-customer (VOC) programs. It argues that customers are a company's most valuable asset, so it is important to understand their perspectives through VOC programs. The document provides 10 hints for effective VOC programs, such as knowing your customers, having a clear objective, compensating respondents, and following up on findings. It encourages companies to engage Trilogy Associates as a partner to help design and implement successful VOC programs.
Addressing the New Realities of Tomorrow\'s Healthcare Environmenttrilogy
The document discusses the need for medical product suppliers to conduct deep due diligence when assessing new products to address the evolving U.S. healthcare system's focus on comparative effectiveness. This means new products must prove they are at least as clinically effective as existing options and more economically effective through reduced costs. Suppliers will need to answer questions about clinical outcomes, economic impacts, and influence on reimbursement policies with compelling data. While "me too" products can easily prove parity, "innovative" products promising better outcomes will require rigorous studies. The document outlines steps and resources needed to properly evaluate new products under these new healthcare realities.
11. Using test-Driven
Development to Write Test
Utility Methods
テストユーティティーに対するテスト→
テストユーティリティーテスト
TDDは、テストユーティリティーメ
ソッドの実装を最小限にするのに役立つ
防護アサーションや、カスタムアサー
ションが有効なので、一般的なロジック
が入る余地はない
12. Where to Put Reuseable
Verification Logic?
再利用可能なテストロジックはどこに置
くか?
もっとも的確なのは、テストケースのク
ラス
テストケースのスーパークラスにpull-up
することもできる。
Test Helperに移動することもできる。
詳しくは12章で